Insmed (IM8N) AI Stock Analysis

9 Followers

Insmed

(XETRA:IM8N)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rapid commercial growthBRINSUPRI has quickly established substantial commercial scale, adding a second major revenue stream alongside ARIKAYCE. Strong payer approvals, reauthorization, persistency, and patient starts support durable adoption and improve Insmed’s ability to compound revenue beyond a single-product model.

Negative Factors

Persistent operating lossesInsmed’s commercial expansion has not yet translated into sustainable profitability, with deeply negative operating and net margins persisting across multiple years. Continued losses weaken earnings quality and mean the company must achieve substantial operating leverage before growth can support durable shareholder returns.

Insmed (IM8N) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 26.49B
Dividend Yield: ―
Average Volume (3M): 81
Price to Earnings (P/E): -42.8
Beta (1Y): 0.17
Revenue Growth: 225.31%
EPS Growth: 56.58%
Country: Germany
Employees: 1,664
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Insmed Business Overview & Revenue Model

Company Description

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult pa...

Insmed Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:23.84%|Next Earnings Date:Feb 25, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by BRINSUPRI's blockbuster launch, 29% sequential quarterly growth, raised guidance for both commercial products, ARIKAYCE regulatory progress, advancing TPIP trials, a strong cash position, and a stated path to cash flow positivity in 2027. The main challenges were a 40% increase in R&D and SG&A expenses, rising ARIKAYCE Medicare coverage costs beginning in 2027, limited visibility into seasonality and the timing of the comorbid bronchiectasis opportunity, long-dated TPIP development timelines, and the CFO transition. Highlights significantly outweighed the lowlights.

Positive Updates

Company Revenue Surpassed $1 Billion Year to Date

Insmed exceeded $1 billion in total company revenue year to date in 2026, reflecting the rapid scale-up of its commercial portfolio.

Negative Updates

Operating Expenses Increased

Combined research and development and SG&A expenses increased 40% compared with the prior-year period due to investments supporting the BRINSUPRI launch and funding the pipeline.

Company Guidance

Insmed raised full-year 2026 BRINSUPRI revenue guidance to $1.35 billion-$1.4 billion and ARIKAYCE revenue guidance to $460 million-$470 million, while reiterating 2026 gross-to-net guidance of mid to high 20s for BRINSUPRI and low to mid-20s for ARIKAYCE; it expects cash flow positivity in 2027. The company forecasted its three lead respiratory assets to collectively grow at a compound annual growth rate of more than 20% over the next 10 plus years and exceed $14 billion in estimated peak sales, with BRINSUPRI peak sales of more than $7 billion, TPIP peak sales of more than $6 billion from four separate indications, and ARIKAYCE peak sales of more than $1 billion. Insmed expects to complete PALM-ILD enrollment no later than the first half of 2028, initiate PALM-IPF in the first half of 2027, begin phase II studies of INS1033 and INS1148 in 2027, share phase I gene therapy data in 2027, and submit one to two INDs per year through the end of the decade.

Insmed Risk Analysis

Insmed disclosed 53 risk factors in its most recent earnings report. Insmed reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Insmed Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:IM8N against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	85Outperform	$25.07B	20.86	19.18%	―	1.89%	0.33%
ALNY	70Outperform	$20.31B	7.84	159.72%	―	56.17%	6459.20%
BMRN	56Neutral	$11.07B	-648.11	-0.31%	―	19.76%	-103.57%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RARE	48Neutral	$1.65B	-3.22	213.22%	―	15.76%	12.63%

* Healthcare Sector Average

Performance Comparison

DE:IM8N and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IM8N	Insmed	107.52	-61.48	-36.38%
ALNY	Alnylam Pharmaceuticals	159.85	-294.12	-64.79%
BMRN	Biomarin Pharmaceutical Inc.	58.33	4.11	7.58%
UTHR	United Therapeutics Corp.	595.66	133.36	28.85%
RARE	Ultragenyx Pharmaceutical, Inc.	16.70	-16.20	-49.24%
AVLN	Avalyn Pharma Inc	31.62	2.13	7.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Insmed AI Stock Analysis